A new report has revealed that Pfizer’s new pill is being developed as a potential cure for COVID-19.
A pill that Pfizer developed as a potential cure for COVID-19 could be ready later this year if the trials are successful, a report said.
The Telegraph reported that the antiviral drug, PF-07321332, is designed to attack the “spine” of the SARS-CoV-2 virus to prevent it from replicating in the nose, throat, and lungs.
“We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care,” Mikael Dolsten, who leads the company’s worldwide research, development, and medical division, said in a statement.
Trials are already underway with volunteers between 18 and 60 in the US and Brussels, the newspaper reported. “If they have moved to this stage, they will be quietly optimistic,” Dr. Penny Ward, a visiting professor in pharmaceutical medicine at King’s College London, told the Telegraph.
The drug company said the first phase of the trial is designed to look at how the drug is tolerated, in addition to “significant side effects, and how people feel after taking it,” according to documents obtained by the newspaper.
The second phase will study how participants react to multiple doses, while the third will look at the impact of eating while on the drug, the outlet reported.
The newspaper reported that more trials would be needed to determine how the drug works with people infected with COVID-19.
If the results of the trials are promising, the oral medication could be available later this year, the outlet reported.
Pfizer and its partner BioNTech have already developed a COVID-19 vaccine that is more than 95 percent effective.
This article originally appeared in the New York Post and was republished with permission.